Today, Astrazeneca PLC (AZN) Rating Increased to Buy at Liberum Capital

Today, Astrazeneca PLC (AZN) Rating Increased to Buy at Liberum Capital

Astrazeneca PLC (NYSE:AZN) was upgraded by analysts at Liberum Capital from a “hold” rating to a “buy” rating in a note issued to investors on Friday.

A number of other analysts have also recently issued reports on the stock. JPMorgan Chase & Co. restated a “neutral” rating on shares of Astrazeneca PLC in a research note on Monday, August 8th. Deutsche Bank AG restated a “buy” rating on shares of Astrazeneca PLC in a research note on Monday, October 10th. Citigroup Inc. restated a “buy” rating on shares of Astrazeneca PLC in a research note on Monday, November 7th. Bank of America Corp. set a $41.00 target price on shares of Astrazeneca PLC and gave the stock a “buy” rating in a research note on Tuesday, October 4th. Finally, Beaufort Securities restated a “hold” rating on shares of Astrazeneca PLC in a research note on Friday, November 11th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. Astrazeneca PLC has an average rating of “Buy” and an average target price of $37.61.

Astrazeneca PLC (NYSE:AZN) traded up 2.50% during mid-day trading on Friday, reaching $27.03. 4,156,551 shares of the company were exchanged. Astrazeneca PLC has a 12-month low of $25.88 and a 12-month high of $35.04. The company’s 50 day moving average price is $29.20 and its 200-day moving average price is $30.75. The stock has a market capitalization of $68.39 billion, a price-to-earnings ratio of 27.74 and a beta of 0.83.

Astrazeneca PLC (NYSE:AZN) last released its earnings results on Thursday, November 10th. The company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.58. The business earned $5.70 billion during the quarter, compared to the consensus estimate of $5.95 billion. Astrazeneca PLC had a net margin of 10.35% and a return on equity of 31.30%. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.03 earnings per share. On average, equities research analysts forecast that Astrazeneca PLC will post $3.02 earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in the stock. First Interstate Bank raised its stake in shares of Astrazeneca PLC by 233.3% in the second quarter. First Interstate Bank now owns 3,900 shares of the company’s stock valued at $118,000 after buying an additional 2,730 shares during the period. Acrospire Investment Management LLC raised its stake in shares of Astrazeneca PLC by 1,078.4% in the third quarter. Acrospire Investment Management LLC now owns 3,606 shares of the company’s stock valued at $118,000 after buying an additional 3,300 shares during the period. Synovus Financial Corp raised its stake in shares of Astrazeneca PLC by 29.7% in the second quarter. Synovus Financial Corp now owns 4,372 shares of the company’s stock valued at $132,000 after buying an additional 1,000 shares during the period. Fifth Third Bancorp raised its stake in shares of Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock valued at $140,000 after buying an additional 103 shares during the period. Finally, Integrated Investment Consultants LLC raised its stake in shares of Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock valued at $144,000 after buying an additional 275 shares during the period. 11.81% of the stock is currently owned by institutional investors.

Astrazeneca PLC Company Profile

Related posts

Leave a Comment